{"id":1732,"date":"2019-09-17T20:05:57","date_gmt":"2019-09-17T18:05:57","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1732"},"modified":"2024-09-19T14:07:06","modified_gmt":"2024-09-19T12:07:06","slug":"prett-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/prett-2\/","title":{"rendered":"Preclinical and experimental research in thoracic tumors (PReTT)"},"content":{"rendered":"\n

\n\t\tPreclinical and experimental research in thoracic tumors (PReTT)\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The PReTT group focuses on the study of novel therapeutic strategies in thoracic tumours combining basic molecular and patient-oriented translational research, bioinformatics, and also design and development of investigator-initiated clinical trials. In terms of basic research, we study the mechanisms through which tumour cells die in response to different treatments and stimuli. Analysing the responses both at cell and tumour microenvironment level, including the immune system and metabolic status. On the translational side, our focus is the validation of diagnostic and treatment response biomarkers in order to improve the clinical management of thoracic tumours. At the bioinformatics level, the aim is to improve the stratification of thoracic tumours and the identification of potentially novel treatments tailored to the molecular characteristics of the patient.<\/p>\n

77<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"108-mortcelular-cmunozpinedo-def\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\u2022 Characterisation of immune-tumour-stroma connections in thoracic tumours to improve therapeutic approaches (Ernest Nadal, Cristina Mu\u00f1oz-Pinedo and Xavier Sol\u00e9)
\n\u2022 Metabolic vulnerabilities of lung cancer and malignant pleural mesothelioma (Cristina Mu\u00f1oz-Pinedo and Ernest Nadal)
\n\u2022 Molecular mechanisms of apoptosis and other forms of cell death induced by metabolic challenges and ischaemia (Cristina Mu\u00f1oz-Pinedo)
\n\u2022 Study of germline and somatic genomic alterations in thoracic tumours in tumour tissue and liquid biopsy (Ernest Nadal and Xavier Sol\u00e9)
\n\u2022 Design and development of clinical trials with a solid scientific rationale (Ernest Nadal)
\n\u2022 Stratification of thoracic tumours based on the computational integration of omic data (Xavier Sol\u00e9 and Ernest Nadal)
\n\u2022 Identification of personalized treatments by integrating large-scale pharmacogenomics data and validated drug-response signatures (Xavier Sol\u00e9)\n\t\t\t\t\t
Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t